Connect with us


Oncology Biosimilar Market 2019 Industry Size by Global Major Companies Profile, Competitive Landscape and Key Regions 2026


The Global Oncology Biosimilar Market is poised for rapid growth as patents of expensive biologic drugs are on the verge of expiration. Key insights in this regard have been shared by Fortune Business Insights, titled “Oncology Biosimilars Market Size, Share and Global Trend by Drug Class (mAb, G-CSF, Hematopoietic Agents, Others), By Type of Cancer (Lung Cancer, Breast Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Geography Forecast till 2026”. The report puts together important factors influencing the market. A biosimilar is a biological product that is highly, but not entirely, similar to its reference biologic. For example, Amjevita became the first approved biosimilar for Humira that is used to treat rheumatoid arthritis and psoriasis.

Browse Complete Report Details at

Some of the major companies that are present in the Global Oncology Biosimilars Market are

  • Sandoz International GmbH,
  • Celltrion Inc.,
  • Pfizer Inc.,
  • Amgen Inc.,
  • Samsung Bioepis,
  • Biogen International,
  • Merck and Co., Inc.,
  • Coherus Biosciences and other players.

Biosimilars Prove to be More Cost-Effective

Even though biologic drugs are highly effective and have fewer side effects, they are expensive and put a great financial burden on the patient. Biosimilars offer the ideal alternative as they are similar to their reference biologic in terms of chemical structure, but cost a lot less than their underlying biologic counterpart. They have also been shown to have high effectiveness in treating diseases. Their demand has been steadily rising in treating cancer patients, who were hitherto being treated by the expensive biologic drugs. The high cost of drugs coupled with even higher consultation and hospital drains patients financially. This has been confirmed by the Agency for Healthcare Research and Quality who estimated that close $80 billion were spent by Americans for cancer treatments in 2015. The need for cost savings by cancer patients is expected to be a key factor in the growth of the global oncology biosimilar market.

Complexity in Manufacturing of Biosimilars Likely to Hinder Its Market Growth

The global oncology biosimilar market may suffer setbacks with regard to the manufacturing of biosimilars. The main reason for this is the complex molecular structure of biosimilars. Pharmaceuticals engaged in manufacturing biosimilars need to invest more in R and D which will push up the costs of their products. They will also have to do multiple clinical tests to prove the efficacy of the drugs. Given their complex nature, obtaining regulatory approvals for biosimilars will be hard, particularly for those treating cancer. For example, prior to the Supreme Court’s ruling, biosimilar applicants had to wait for six months to get FDA approval. This might negatively impact the growth of the global oncology biosimilar market.

Get Sample PDF Brochure

Strong Competition is Expected to Make the Market Dynamic

Competitors are taking decisive steps to stay ahead of the curve in the global oncology biosimilar market. This is being mainly done through diversifying product portfolios, the introduction of innovative products, filing for patents, and increased investment in research. For example, Pfizer’s oncology biosimilar, Trazimera, received FDA approval in early 2019. The drug has been developed to treat multiple types of cancer. The potential held by this fast-growing market is likely to increase the intensity of competition during the forecast period.

Fortune Business Insights identifies the key players in the global oncology biosimilar market which include Pfizer, Merck and Co., Inc., Biogen International, Samsung Bioepis, Sandoz International, among others.

Among Regional Markets, North America and Europe to Have the Largest Share

Higher prevalence of cancer and the establishment of regulatory frameworks will keep North America and Europe as dominant contributors in the global oncology biosimilar market in the forecast period. Asia-Pacific is also slated to emerge as a strong regional market, mainly owing to the growing populations and healthcare awareness in India and China. The Associated Chamber of Commerce reports that the global oncology biosimilar market will reach $240 billion and the Indian market would touch $35 billion by 2030.

View Related Report at

Contraceptive Drugs Market 2019 Global Industry Trends, Share, Size, Demand, Growth Opportunities, Industry Revenue, Future and Business Analysis by Forecast 2025

Cocoa and Chocolate Market 2019 Global Industry Size, Future Trends, Growth Key Factors, Demand, Scope, and Opportunities Analysis by Outlook 2025

Seed Treatment Market 2019 Global Industry Trends, Share, Size, Demand, Growth Opportunities, Industry Revenue, Future and Business Analysis by Forecast 2025

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected]


MingZhu Logistics Holdings Limited Announces Closing of US$12.0 Million Firm Commitment Initial Public Offering


SHENZHEN, Oct. 24, 2020 /PRNewswire/ — MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (NASDAQ: YGMZ), a China-based trucking services provider, today announced the closing of its firm commitment initial public offering of 3,000,000 ordinary shares at a public offering price of $4.00 per share, for total gross proceeds of US$12 million, before deducting underwriting discounts, commissions and other related expenses. In addition, MingZhu has granted the underwriters a 45-day option to purchase up to an additional 450,000 ordinary shares at the public offering price, less underwriting discount and commissions. The shares began trading on the NASDAQ Capital Market on October 21, 2020 under the ticker symbol "YGMZ".

ViewTrade Securities, Inc., a global provider of brokerage, investment banking, corporate /advisory and trading platform services, acted as sole book-running manager for the offering.

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission (SEC) on September 30, 2020. The offering of these securities was made only by means of a prospectus, forming a part of the registration statement. A copy of the final prospectus related to the offering may be obtained, when available, from ViewTrade Securities, via email: [email protected] or standard mail at ViewTrade Securities, 7280 W Palmetto Park Rd, #310, Boca Raton, FL 33433, Attn: Prospectus Department. In addition, a copy of the final prospectus relating to the offering may be obtained via the SEC’s website at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About MingZhu Logistics Holdings Limited

Founded in 2002 and Headquartered in Shenzhen, China, MingZhu is 3A-grade trucking services provider, offering both network density and broad geographic coverage to meet customers’ diverse transportation needs. The Company operates two regional terminals in Guangdong Province and Xinjiang Autonomous Region, respectively, with a mix of self-own fleets of tractors and trailers and subcontractors’ fleets. More information about MingZhu can be found at:

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the trucking services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

At the Company:

Dennis Tan
Email: [email protected]
Phone: (+86) 150-1854-1833

Investor Relations:

Tony Tian, CFA 
Weitian Group LLC
Email: [email protected]
Phone: (+1) 732-910-9692

Continue Reading


Expanse Exceeds 100 Percent Year Over Year Growth in 2020, Dominating Attack Surface Management Market


Expanse Inc., the global leader in attack surface management, announced another year of hyper growth to dominate the attack surface management category. From September 2019 to September 2020, Expanse doubled revenues from the previous year and saw the total value of customer wins exceed $100M. Driven by growth from both the private and public sector, Expanse doubled customer count, including several seven-plus figure deals as more enterprises adopted attack surface management accelerated by digital transformation.

Expanse indexes every system and service on the public internet to continuously monitor its customers global Internet attack surface, making it easy for security professionals to take action. From misconfigured servers to cloud instances, applications IT is unaware of components or devices banned by governments, Expanse allows security professionals to see the full picture of their attack surface.

Our remarkable growth has been driven by the gap created when companies rapidly embark on digital transformation, said Tim Junio, Expanse CEO. Our results show not only the growth of the attack surface management category, but also Expanses commanding lead in this burgeoning discipline. Moreover, our rapid rate of adoption of our solutions demonstrates the growing need for a dedicated and continuous ability to manage and secure changing assets that sit far outside a dissolving perimeter.

With the addition of several new customers during 2020, Expanse continues to serve an elite customer base including:

  • Fortune 500 customers such as CVS, Paypal, and Accenture.
  • Every major branch of the military including the Army, Navy, Air Force, Marine Corps and Coast Guard.
  • Multiple departments of the federal government including the State Department, the Department of Energy and other Cabinet-level departments, agencies, and federal corporations delivering essential services.

Growth highlights

In addition to Expanses rapid revenue growth, the company also:

  • Maintained a net customer retention rate of over 150% in the past 12 months.
  • Doubled hiring targets for its sales force and added Kane Lightowler as Chief Revenue Officer who led sales at several high-growth technology companies including Carbon Black and Imperva.
  • Discovered and helped to remove over 35,000 critically exposed systems managed by customers from the public Internet.

Product innovations

Expanse introduced several new and innovative capabilities that help customers scope and remediate their unique attack surface including:

  • Next-generation asset attribution engine further extends Expanses technical leadership as the most accurate and complete solution for discovering customer assets on the global Internet. The companys updated engine extends proprietary semi-supervised machine learning technology to get better-than-human accuracy across multiple asset categories.
  • Issues policy engine allowing customers to identify issues or misconfigurations that increase customer visibility into risk. After Expanse discovers all Internet assets and associated services belonging to the organization, the policy engine detects security policy violations according to the unique needs of the organization.
  • Third-party integrations to help fit into a wide range of different customer environments to increase operational efficiency and improve visibility. Integrations included QRadar, Cortex XSOAR and Tenable.
  • Added cloud misconfiguration types to provide the broadest range of cloud risk management coverage on the market.

Most businesses have complex interconnections of servers, cloud instances, desktops, laptops, mobile devices, Internet of Things (IoT) and more, said Shilpi Handa, Gartner analyst in The Essential Elements of Effective Vulnerability Management (October 2020).These assets are dynamic, seemingly borderless, and continuously moving and growing. As this footprint increases, so does the organizations threat exposure. Maintaining asset inventory is fundamental to any robust cybersecurity program and being cognizant of this inventory is fundamental to a vulnerability management program.

Laurel Toney

[email protected]

Continue Reading


INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Evolus, Inc. (EOLS) Investors


Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Evolus, Inc. (Evolus or the Company) (NASDAQ: EOLS) securities between February 1, 2019 and July 6, 2020, inclusive (the Class Period). Evolus investors have until December 15, 2020 to file a lead plaintiff motion.

Investors suffering losses on their Evolus investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

On July 6, 2020, the U.S. International Trade Commission (ITC) issued its Final Initial Determination in a case alleging that Evolus stole certain trade secrets to develop Jeuveau„¢. The ITC Judge found that Evolus misused the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture. As a result, the ITC Judge recommended a ten-year long ban on Evolus ability to import Jeuveau„¢ into the United States and a ten-year long cease and desist order preventing Evolus from selling Jeuveau„¢ in the United States.

On this news, Evolus share price declined dramatically, falling 37% over the course of two trading days, to close at $3.35 on July 8, 2020, thereby injuring investors.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the actual source of botulinum toxin bacterial strain, along with the manufacturing processes used to develop Jeuveau, originated with and were misappropriated from Medytox; (2) that adequate evidentiary support existed for the allegations that the Company misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau; (3) as a result, Evolus faced a actual danger of regulatory and/or court action, ceasing the import, marketing, and sale of Jeuveau; (4) which in turn jeopardized the Companys ability to commercialize Jeuveau in the United States and generate revenue; and (5) that any revenues generated from the sale of Jeuveau were based on Evolus’ unlawful actions, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox; and (6) that, as a result, the Companys public statements were materially false and misleading at all relevant times.

If you purchased Evolus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith

Howard G. Smith, Esquire



[email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News44 mins ago

MingZhu Logistics Holdings Limited Announces Closing of US$12.0 Million Firm Commitment Initial Public Offering

SHENZHEN, Oct. 24, 2020 /PRNewswire/ — MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (NASDAQ: YGMZ), a China-based trucking services...

gbafNews28 gbafNews28
News2 hours ago

Expanse Exceeds 100 Percent Year Over Year Growth in 2020, Dominating Attack Surface Management Market

Expanse Inc., the global leader in attack surface management, announced another year of hyper growth to dominate the attack surface...

gbafNews28 gbafNews28
News2 hours ago

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Evolus, Inc. (EOLS) Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who...

gbafNews28 gbafNews28
News2 hours ago

KBRA Assigns Preliminary Ratings to Dext ABS 2020-1, LLC

Kroll Bond Rating Agency (KBRA) assigns preliminary ratings to four classes of notes issued by Dext ABS 2020-1, LLC, an...

gbafNews28 gbafNews28
News2 hours ago

Singleton Law Firm Sues PGE on Behalf of Santiam Canyon Fire Victims

Singleton Law Firm, a leading West Coast fire litigation law firm, recently filed a lawsuit against Portland General Electric (PGE)...

gbafNews28 gbafNews28
News2 hours ago

QM Environmental Receives Gold Award at Canada’s Safest Employers Awards

QM Environmental (“QM” or the “Company“), a leading Canadian environmental and industrial services company, was announced as the gold winner...

gbafNews28 gbafNews28
News2 hours ago

CUPE Says Rapid Testing at Calgary Airport a Solid Step, Calls for Other Airports to Follow Suit

CUPE 4070 is praising the announcement of rapid COVID testing at the Calgary airport. The union says the announcement is...

gbafNews28 gbafNews28
News2 hours ago

K-12 Online Tutoring Market | Growing Importance of STEM Education to Boost Market Growth | Technavio

The global K-12 online tutoring market size is poised to grow by USD 80.18 billion during 2020-2024, progressing at a...

gbafNews28 gbafNews28
News2 hours ago

Dorsey Recognized as a 2020 Best Adoption-Friendly Workplace by Dave Thomas Foundation for Adoption

International law firm Dorsey & Whitney LLP is pleased to announce that the Dave Thomas Foundation for Adoption, in its...

gbafNews28 gbafNews28
News3 hours ago

PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine Candidate

Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder...